1012 related articles for article (PubMed ID: 29274022)
1. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
Pichi F; Elbarky AM; Elhamaky TR
Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
[TBL] [Abstract][Full Text] [Related]
2. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
[TBL] [Abstract][Full Text] [Related]
3. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
4. Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.
Chatziralli I; Theodossiadis G; Moschos MM; Mitropoulos P; Theodossiadis P
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1093-1100. PubMed ID: 28214955
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Ranibizumab versus Aflibercept in Treating Macular Edema among Patients with Serous Retinal Detachment Secondary to Branch Retinal Vein Occlusion.
Küçük B; Sirakaya E; Karaca C
Ocul Immunol Inflamm; 2021 Feb; 29(2):403-410. PubMed ID: 31718358
[No Abstract] [Full Text] [Related]
6. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.
Konidaris V; Al-Hubeshy Z; Tsaousis KT; Gorgoli K; Banerjee S; Empeslidis T
Int Ophthalmol; 2018 Feb; 38(1):207-213. PubMed ID: 28405787
[TBL] [Abstract][Full Text] [Related]
7. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.
Li F; Sun M; Guo J; Ma A; Zhao B
Curr Eye Res; 2017 Aug; 42(8):1174-1178. PubMed ID: 28441077
[TBL] [Abstract][Full Text] [Related]
9. The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion.
Lehmann-Clarke L; Dirani A; Mantel I; Ambresin A
Klin Monbl Augenheilkd; 2015 Apr; 232(4):552-5. PubMed ID: 25902119
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
11. Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema.
Goel S; Kumar A; Ravani RD; Chandra P; Chandra M; Kumar V
Indian J Ophthalmol; 2019 Jul; 67(7):1105-1108. PubMed ID: 31238421
[TBL] [Abstract][Full Text] [Related]
12. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion.
Son BK; Kwak HW; Kim ES; Yu SY
Korean J Ophthalmol; 2017 Jun; 31(3):209-216. PubMed ID: 28471106
[TBL] [Abstract][Full Text] [Related]
14. Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusions: A Meta-Analysis.
Spooner K; Hong T; Fraser-Bell S; Chang AA
Ophthalmologica; 2019; 242(3):163-177. PubMed ID: 31158837
[TBL] [Abstract][Full Text] [Related]
15. Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial.
Song S; Yu X; Zhang P; Gu X; Dai H
BMC Ophthalmol; 2020 Jun; 20(1):241. PubMed ID: 32560639
[TBL] [Abstract][Full Text] [Related]
16. Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion.
Kaya F; Kocak I; Aydin A; Baybora H; Koc H; Karabela Y
J Fr Ophtalmol; 2018 Nov; 41(9):809-813. PubMed ID: 30361176
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Altaweel M; Berinstein DM;
JAMA Ophthalmol; 2018 Apr; 136(4):337-345. PubMed ID: 29476687
[TBL] [Abstract][Full Text] [Related]
18. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
Ozkaya A; Tarakcioglu HN; Tanir I
Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
[TBL] [Abstract][Full Text] [Related]
19. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
Larsen M; Waldstein SM; Priglinger S; Hykin P; Barnes E; Gekkieva M; Das Gupta A; Wenzel A; Monés J;
Ophthalmol Retina; 2018 Feb; 2(2):134-142. PubMed ID: 31047340
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
